8-K: Cabaletta Bio Announces Positive Initial Clinical Data for CABA-201 in Autoimmune Trials

Cabaletta Bio reports positive initial clinical data from its Phase 1/2 trials of CABA-201, showing promising results in patients with myositis and lupus.

Summary

• Cabaletta Bio has released initial clinical data from the first two patients treated with CABA-201 in Phase 1/2 trials for myositis and lupus.
• The data, presented at the EULAR 2024 Congress, showed that CABA-201 was generally well-tolerated with no serious adverse events, cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS).
• Both patients experienced complete B cell depletion within 15 days post-infusion.
• The myositis patient showed a decrease in creatinine kinase from 617 to 308 and a total improvement score (TIS) of 30 after 12 weeks.
• The lupus patient's SLEDAI-2K score improved from 26 at baseline to 10 after 4 weeks.
• B cell repopulation with immature, naive B cells was observed in the myositis patient at week 8, suggesting a potential immune system reset.
• The company is advancing four Phase 1/2 RESET trials evaluating CABA-201 in ten cohorts with six patients each, using a single dose of 1 x 10^6 cells/kg.
• As of May 28, 2024, one myositis patient had completed three months of follow-up, and one lupus patient had completed one month of follow-up.

Sentiment

Score: 8

Explanation: The document presents very positive initial clinical data with a strong emphasis on safety and efficacy, suggesting a promising outlook for the company's lead product candidate. The comparison to academic studies and the potential for a paradigm shift in autoimmune treatment contribute to a high sentiment score.

Positives

• CABA-201 was well-tolerated with no serious adverse events, CRS, or ICANS.
• Both patients achieved complete B cell depletion within 15 days.
• The myositis patient showed a reduction in creatinine kinase and a TIS of 30.
• The lupus patient's SLEDAI-2K score improved from 26 to 10.
• B cell repopulation with naive B cells was observed in the myositis patient.
• The CAR T cell expansion was consistent with academic studies.
• All chronic maintenance therapies were discontinued for both patients, except for a planned prednisone taper for the SLE patient.
• Vaccination titers were preserved post-infusion, with no reported infections.

Negatives

• Both patients experienced early, transient leukopenia, as expected with the preconditioning regimen.
• The SLE patient experienced Grade 4 leukopenia, neutropenia and lymphopenia which resolved and were attributed to the preconditioning regimen.

Risks

• The long-term efficacy and safety of CABA-201 are still being evaluated.
• The results observed in the first two patients may not be indicative of results in a larger patient population.
• There are risks related to regulatory filings and potential clearance.
• Clinical trial site activation and patient enrollment may face delays.
• Unexpected safety or efficacy data may emerge during clinical studies.
• The company faces risks related to volatile market and economic conditions and public health crises.
• There are risks related to the company's ability to protect and maintain its intellectual property position.
• The company faces uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates.

Future Outlook

Cabaletta expects to report initial clinical data from the Phase 1/2 RESET-SSc and RESET-MG trials, as well as additional data from the RESET-Myositis and RESET-SLE trials, in the second half of 2024. The company is also working to accelerate clinical trial enrollment and advance its pipeline.

Management Comments

• David J. Chang, M.D., Chief Medical Officer of Cabaletta, stated that the initial safety, clinical, and translational data provide important early validation regarding the potential of CABA-201 to enable an immune system reset.
• Management believes CABA-201 may be uniquely positioned to fulfill unmet patient needs across a broad range of autoimmune diseases.

Industry Context

This announcement is significant as it provides early clinical data supporting the use of CAR T cell therapy in autoimmune diseases, an area with high unmet medical need. The results are being compared to academic studies using similar constructs, suggesting a potential paradigm shift in the treatment of these conditions.

Comparison to Industry Standards

• The CABA-201 results are being compared to academic studies using a similar 4-1BB CD19-CAR T construct, notably the work of the University Hospital Erlangen group, which reported durable remissions in autoimmune patients.
• The observed B cell depletion and repopulation patterns are consistent with those seen in the academic studies.
• The safety profile, with no reported CRS or ICANS, is also being compared to the academic data, which reported mostly mild CRS events.
• The clinical improvements in myositis and lupus patients are being benchmarked against the outcomes reported in the academic case series, where patients achieved significant disease reduction and were able to discontinue immunosuppressive therapies.
• The company is also referencing the expansion profile of BCMA-CAR T products in multiple myeloma, where the number of target cells is more similar to autoimmune disease than to B cell leukemias and lymphomas.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical data.
• Patients with autoimmune diseases may see hope for new, potentially curative treatments.
• Employees may be motivated by the positive progress of the company's research.
• The results may attract interest from potential partners and investors.

Next Steps

• Cabaletta plans to continue enrolling patients in the RESET clinical program.
• The company expects to report initial clinical data from the RESET-SSc and RESET-MG trials in the second half of 2024.
• Additional data from the RESET-Myositis and RESET-SLE trials are also expected in the second half of 2024.
• The company is advancing the process to activate clinical trial sites and pursue patient enrollment.
• Cabaletta plans to assess its DesCAARTes and MusCAARTes trials.

Key Dates

Keywords

CABA-201, CAR T cell therapy, autoimmune disease, myositis, lupus, RESET trials, B cell depletion, immune system reset, clinical data, EULAR 2024